EGFR and lung adenocarcinoma: Further, as PLAUR overexpression was shown to induce gefitinib resistance through the EGFR/p-AKT/surviving signaling pathway in cell models of human lung adenocarcinoma (84), strategies that downregulate PLAUR could also be explored to avoid EGFR-targeted resistance mechanisms.